Free tool
FAERS Monitor: Bludigo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216264 or its brand name (Bludigo, Indigotindisulfonate Sodium). Reports on generic versions are filed under their own applications.
Reports
4
Serious
4
100% of reports
Hospitalization
1
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaphylactic reaction1
- cheilitis1
- dermatitis1
- drug ineffective1
- extravasation1
- radiation skin injury1
- reaction to excipient1
- stomatitis1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2015 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radiation skin injury | 1 | 4541.4 | 831.0 | 1,133 |
| reaction to excipient | 1 | 2279.6 | 417.3 | 569 |
| extravasation | 1 | 1279.7 | 234.3 | 319 |
| cheilitis | 1 | 972.0 | 178.0 | 242 |
| dermatitis | 1 | 251.0 | 46.0 | 62 |
| anaphylactic reaction | 1 | 95.2 | 17.4 | 23 |
| stomatitis | 1 | 86.7 | 15.9 | 21 |
| drug ineffective | 1 | 4.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.